Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Allergan Diversifies With Deals For Migraine Therapies, Ophthalmologic Device

Executive Summary

AMAG adds to its commercial and technological capabilities with a buyout of Cord Blood Registry. Meanwhile, ramifications of the GSK/Novartis asset swap from March continue, with GSK divesting a pair of vaccines to Pfizer, while Novartis acquires Australian biotech Spinifex.

Advertisement

Related Content

Allergan Moves Into Busy CGRP Class By Buying Merck’s Oral Drugs
Swapping Assets Now Down To Execution For GSK And Novartis
Can “Novel-Novel” Drug Development Work? Deals Of The Week Considers Merck’s New Play
Merck Gets A Headache: Unexpectedly Halts Development Of Migraine Drug

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056995

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel